Drugs / UCART20x22
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05607420 | Nov 2022 → Aug 2027 expected | B-cell non-Hodgkin lymphoma | Cellectis S.A. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Cellectis S.A. | Results Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress cellectis.com ↗
These encouraging data demonstrate that not only can eti-cel drive responses in a very difficult-to-treat population, but that by optimizing exposure to alemtuzumab we may be able to create a favorable environment for CAR-T expansion and persistence. |
| 2025-11-03 | Cellectis S.A. | Results Cellectis to Present a Development Update for eti-cel at ASH 2025 cellectis.com ↗
Cellectis unveiled preliminary results on eti-cel, which demonstrate an encouraging overall response rate (ORR) of 86% and a complete response (CR) rate of 57% at the current dose level (n=7), with 4 out of 7 patients achieving a complete response. |
| 2025-10-16 | Cellectis S.A. | Results Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL cellectis.com ↗
These preliminary results demonstrate an encouraging overall response rate (ORR) of 86% and a complete response (CR) rate of 57% at the current dose level (n=7), with 4 out of 7 patients achieving a complete response. |
| 2023-11-02 | Cellectis S.A. | Results Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting cellectis.com ↗
The poster presentation highlights the following data: as of July 1, 2023, 3 patients were enrolled and treated at dose level 1 (50 million cells) with product manufactured in-house by Cellectis. |
| 2023-06-05 | Cellectis S.A. | Results Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event cellectis.com ↗
Cellectis demonstrates that UCART20x22 displays robust activity in vitro and in vivo, against targets expressing heterogeneous levels of CD22 and CD20. |
| 2023-05-31 | Cellectis S.A. | Results Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies cellectis.com ↗ |
| 2022-08-01 | Cellectis S.A. | Regulatory Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies cellectis.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL). |
| 2022-04-08 | Cellectis S.A. | Results Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting cellectis.com ↗ |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCART20x22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05607420 ↗ |
| Modality | Cell therapy | “Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors” NCT05607420 ↗ |
| Route | Intravenous | “UCART20x22 administered intravenously” NCT05607420 ↗ |